Calmark signs distributor agreement with Prime Biosciences in Greece
Calmark Sweden AB (publ) has entered an exclusive distributor agreement with the company Prime Biosciences regarding marketing and sales of the Calmark POC system on the Greek market.
Prime Biosciences was founded in 2018 and offers a wide range of services in health care in Greece. The company has established relationships with both private and public hospitals and laboratories as well as a broad customer base of e.g. pediatricians and neonatologists.
“It feels great to launch our product in Greece where there is a great need for point-of-care diagnostics. Calmark Neo enables testing of children even when they are on any of the many islands”, says Magdalena Tharaldsen, Director International Business Development for Calmark. "I look forward to a rewarding collaboration with this committed distributor!"
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
This disclosure contains information that Calmark Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 31-05-2022 09:21 CET.
For more information about Calmark Sweden AB, please contact:
Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se
www.calmark.se
Calmark Sweden AB is a medical technology company that develops and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark sells a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.
Tags:
